Versant Ventures (Ridgeline Discovery)

1. Executive Summary (Confidence: High)

Ridgeline Discovery, founded in 2017 in Basel, Switzerland, represents a central pillar of Versant Ventures’ unique "hands-on" approach to company building. As a "Discovery Engine," Ridgeline is not merely a financial vehicle but a fully operational research site staffed by an international team of industry R&D veterans. Its primary mission is to source breakthrough science from European academic institutes and develop it into independent, foundational biotech companies.

With Versant Ventures managing over $5.5 billion in capital, Ridgeline leverages deep investment, research, and operating expertise to de-risk early-stage science through in-house laboratory validation. The organization has successfully launched multiple independent biotech leaders, including Black Diamond Therapeutics, Bright Peak Therapeutics, and Monte Rosa Therapeutics. By importing "Big Pharma" discipline into the venture space, Ridgeline has become a primary driver of the Swiss and European longevity and oncology biotech ecosystem.